Limitations of current therapies to prevent thrombosis: a need for novel strategies

Antagonists of the EP3Receptor for Prostaglandin E2Are Novel Antiplatelet Agents That Do Not Prolong Bleeding

(2009) Jasbir Singh et al.   ACS Chemical Biology

Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel

(2009) Jessica L. Mega et al.   CIRCULATION

Novel antiplatelet strategies in acute coronary syndromes

(2009) M. S. SABATINE   CLEVELAND CLINIC JOURNAL OF MEDICINE

Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study

(2009) Richard C Becker et al.   LANCET

Loss of SR-A and CD36 Activity Reduces Atherosclerotic Lesion Complexity Without Abrogating Foam Cell Formation in Hyperlipidemic Mice

(2008) Jennifer J. Manning-Tobin et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Coexisting Polymorphisms of P2Y12 and CYP2C19 Genes as a Risk Factor for Persistent Platelet Activation With Clopidogrel

(2008) Lukasz A. Malek et al.   CIRCULATION JOURNAL

Function of von Willebrand factor in haemostasis and thrombosis

(2008) A. J. REININGER   HAEMOPHILIA

Mechanisms of Thrombus Formation

(2008) Bruce Furie et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cytochrome P-450 Polymorphisms and Response to Clopidogrel

(2008) Jessica L. Mega et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genetic Determinants of Response to Clopidogrel and Cardiovascular Events

(2008) Tabassome Simon et al.   NEW ENGLAND JOURNAL OF MEDICINE

DG-041 inhibits the EP3 prostanoid receptor—A new target for inhibition of platelet function in atherothrombotic disease

(2008) Stan Heptinstall et al.   PLATELETS